Innovent Biologics, a leading global biopharmaceutical company specializing in the development, manufacture, and commercialization of high-quality medicines for oncology, cardiovascular and metabolic diseases, autoimmune conditions, ophthalmology, and other critical areas, has announced a strategic partnership with WeComput. This collaboration aims to advance Innovent’s Artificial Intelligence (AI) for Drug Discovery platform, leveraging AI technology to accelerate drug discovery and development processes.
The partnership will see Innovent Academy, a pivotal R&D engine within Innovent, utilize WeComput’s WeMol molecular design platform to enhance its computing infrastructure. This integration is expected to significantly accelerate drug research and development. Additionally, WeMol will incorporate NVIDIA’s BioNeMo technology to expand the computing capabilities of Innovent’s AI systems, thereby improving computational efficiency.
The joint effort will result in the creation of a sophisticated AI-driven drug discovery and development system characterized by efficiency, user-friendliness, digitalization, intelligence, and automation. This system is anticipated to reduce the costs associated with AI implementation and experimentation, shorten the drug R&D cycle, increase the success rate of R&D activities, and ultimately deliver innovative drugs and treatment options to patients more effectively.
Dr. Kaijie He, Vice President of Oncology Biology and ADC Drug Research at Innovent, expressed enthusiasm about the partnership, stating, “AI is injecting new momentum into the global pharmaceutical and biotech industries. We are excited to collaborate with WeComput and integrate advanced AI technology to enhance our R&D capabilities and expedite the discovery and development of groundbreaking drugs. This collaboration will provide substantial technical support to our research team, driving us towards significant breakthroughs in the global pharmaceutical market.”
Harry (Hu) Ge, CEO of WeComput, also highlighted the mutual benefits of the collaboration, saying, “This partnership will be advantageous for both parties, promoting the broader application of AI technology within the biopharmaceutical sector and fostering innovation and development in the global pharmaceutical industry.”
Together, Innovent and WeComput are poised to transform the landscape of drug discovery and development, harnessing the power of AI to address complex medical challenges and advance patient care.
Read More: Click Here
